Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07130019

Is Monitoring Enhanced Auto-fluorescence Beneficial for the Precise Removal of Tissue From Psoriatic Lesions With Ablative Lasers?

It is known that psoriatic lesions clear and remain cleared if you remove them from the skin. This can be done through surgery and ablative laser therapy. In order for the treatment to be succesful, you need to remove the complete epidermis and a bit of the dermis (the upper part of the skin). In psoriasis, the thickness of that part of the skin can vary significantly. Incomplete removal results in the return of the lesion. A challenge is that you can't easily tell how deep into the skin you are. Not only is the skin quite thin (from 0.1 mm to 1.0 mm), at the boundary they look quite similar. If you go too deep, you get scarring. Thus there is a need to delineate the psoriatic tissue from the healthy tissue.

We think that one way to do that is by looking at the fluorescence of the skin. If you shine a particular shade of blue light on the skin, it gives off red light. But this is only true for the part where the psoriasis can reside. Under normal circumstances this fluorescence is too weak to really see with the eye. Thus we first increase the fluorescence by administering a compound that is used to make the fluorescent molecules in our tissue, 5-aminolevulinic acid (5-ALA). It can be quite difficult to get 5-ALA into the skin. To help the 5-ALA, we use a very superficial lasertreatment to poke minute holes in the skin. The 5-ALA enters the skin and the fluorescence builds up. After a couple of hours, the skin is treated with a laser that can gently remove the tissue. Layer for layer is removed until there is no more fluorescence. At that point we do one more pass to be sure, and then stop. We hope that two months later, the psoriasis is gone and will remain so for at least a year.

We think that the fluorescence helps, but we can't be sure. So for that reason we will also treat a lesion without fluorescence and use the standard method to judge how deep we have treated the skin. And to rule out the possibility that e.g. sun exposure cleared the lesions, we also leave one lesion untreated.

Participants have to travel to the clinic for the treatment and then every three to five days for two weeks. Since we remove the skin, there will be a wound that needs healing and attending to. This will result in some limitations during the wound healing phase. Afterwards, you might see some temporary shifts in pigmentation.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–64 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

ZBC Multicare

Hilversum, North Holland, 1217AB, Netherlands

Location contact

M.E. Schram, Ph.D., M.D.

PRINCIPAL_INVESTIGATOR

Nick van der Beek, Ph.D, LL.M, M.Sc

CONTACT

[email protected]

+31356249576

Nick van der Beek, Ph.D, LL.M, M.Sc

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of psoriasis vulgaris of any severity with at least three discrete lesions in optically non-obscured skin located on torso, abdomen, dorsum, legs, arms, face or buttocks.

Exclusion criteria

  • Pregnancy or breastfeeding.
  • Rheumatoid and psoriatic arthritis
  • Fitzpatrick skin type >4.
  • Known allergy to 5-aminolevulinic acid (5-ALA) or light sensitivity.
  • Autoimmune disorders.
  • Heavy smoking.
  • Diabetes mellitus type 2
  • Active bacterial or viral infections in the treatment area
  • Recent use of isotretinoin
  • Morbid obesity
  • History of hypertrophic scaring or keloids
  • History of complicated wound healing
  • Body dysmorphic disorder
  • Use of anti-coagulants
  • Use of cyclosporin A or similar immunosuppressive medication
  • Increase in disease severity during the preceding 8 weeks.
  • If treatment area is on the legs: Severe venous insufficiency, severe lymphoedema or angiopathy.

Treatment and study plan

Fluorescence guided thermal ablation of epidermal tissue

Procedure

Thermal ablation of epidermal tissue under fluorescence control.

Thermal ablation of epidermal tissue

Procedure

Thermal ablation of skin tissue a vue

Primary outcomes

  1. PGA

    Time frame: 8 weeks

    PGA value (0 - 7)

  2. Remission

    Time frame: 8 weeks

    Remission score (0,1)

Secondary outcomes

  1. Healing time

    Time frame: 8 weeks

    Healing time in weeks

Study contacts

Contact information is provided by the study sponsor or research team.

Nick van der Beek, PhD, LL.M, M.Sc

CONTACT

[email protected]

+31356249576

Sponsors and collaborators

Lead sponsor

Nick van der Beek

Other

Registry information

Official study title

Autofluorescence-Guided Removal of Psoriatic Tissue

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Aug 19, 2025
Registry last updated
Aug 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.